2.21  -0.03 (-1.34%)		10-30 16:00
Open: 2.19 High: 2.25 Volume: 1,111,241		Pre. Close: 2.24 Low: 2.095 Market Cap: 247(M)

Short term
Mid term
Targets	6-month :	2.73	1-year :	3.18
Resists	First :	2.34	Second :	2.73
Pivot price	1.97
Supports	First :	1.72	Second :	1.43
MAs	MA(5) :	2.12	MA(20) :	1.97
	MA(100) :	1.9	MA(250) :	1.9
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	89.1	D(3) :	82.1
RSI	RSI(14): 60.4
52-week	High :	2.75	Low :	1.09

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ALEC ] has closed below upper band by 11.6%. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.25 - 2.27	2.27 - 2.28
Low:	2.07 - 2.08	2.08 - 2.09
Close:	2.19 - 2.21	2.21 - 2.23

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Fri, 30 Oct 2026
Alector, Inc. (ALEC) stock price, news, quote and history - Yahoo Finance UK

Thu, 29 Oct 2026
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know - Yahoo Finance

Mon, 19 Oct 2026
Alector: Maintaining 'Hold' ABC Platform Transition And GCase Partnership With Roche - Seeking Alpha

Fri, 16 Oct 2026
Alector Announces Pricing of Underwritten Offering - Yahoo Finance

Fri, 16 Oct 2026
Alector stock rises after pricing equity offering (ALEC:NASDAQ) - Seeking Alpha

Thu, 15 Oct 2026
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments - Slideshow (NASDAQ:ALEC) 2026-10-15 - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	112 (M)
Shares Float	82 (M)
Held by Insiders	7.3 (%)
Held by Institutions	70.2 (%)
Shares Short	6,150 (K)
Shares Short P.Month	6,170 (K)

EPS	-1.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.1
Profit Margin	0 %
Operating Margin	-734.8 %
Return on Assets (ttm)	-27.7 %
Return on Equity (ttm)	-385.2 %
Qtrly Rev. Growth	-57.8 %
Gross Profit (p.s.)	-0.77
Sales Per Share	0.12
EBITDA (p.s.)	-1.07
Qtrly Earnings Growth	0 %
Operating Cash Flow	-158 (M)
Levered Free Cash Flow	-107 (M)

PE Ratio	-2.07
PEG Ratio	0
Price to Book value	-24.56
Price to Sales	17.8
Price to Cash Flow	-1.56

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.